Adrenergic β1 Receptors
The adrenergic β1 receptor (β1-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β2 and β3. They are located primarily in the CNS, heart, coronary artery, kidney and muscle.
Adrenergic β1 Receptor Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 0950 | Xamoterol hemifumarate |
| Selective β1 partial agonist | |
Adrenergic β1 Receptor Antagonists |
|
| Cat. No. | Product Name / Activity |
| 0906 | Betaxolol hydrochloride |
| Selective β1 antagonist | |
| 1024 | CGP 20712 dihydrochloride |
| Highly potent and selective β1 antagonist | |
| 3256 | Metoprolol tartrate |
| Selective β1 antagonist | |
| 3517 | Nebivolol hydrochloride |
| Highly selective β1-adrenoceptor antagonist | |
The adrenergic β1 receptor (β1-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β2 and β3. They are located primarily in the CNS, heart, coronary artery, kidney and muscle and are involved in cardiac stimulation, coronary vasodilation and relaxation of the colon and esophagus. The human adrenergic β1 receptor gene has been localized to chromosome 10 (10q24-q26).
External sources of pharmacological information for Adrenergic β1 Receptors :
Literature for Adrenergic β1 Receptors
Tocris offers the following scientific literature for Adrenergic β1 Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Written by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDF